%PDF-1.4
%
39 0 obj
<>
endobj
36 0 obj
<>
endobj
101 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-05-11T16:16:34Z
2024-03-29T05:40:04-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T05:40:04-07:00
application/pdf
Heather
2002-790.june
uuid:11f2be12-1dd2-11b2-0a00-ca09275d6100
uuid:11f2be15-1dd2-11b2-0a00-aa0000000000
endstream
endobj
25 0 obj
<>
endobj
26 0 obj
<>
endobj
40 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 13 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 15 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
115 0 obj
[119 0 R]
endobj
116 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 10 0 0 10 54 713.0005 Tm
(SAA1)Tj
/T1_2 1 Tf
0 Tc [-0.2 (\003)]TJ
/T1_1 1 Tf
[-0.1 (/)]TJ
/T1_2 1 Tf
[0.2 (\003)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.23669 Tw 4.0865 0 Td
(genotype were lower than those of individuals)Tj
0.02499 Tw -4.0865 -1.2 Td
(with other SAA1 genotypes)Tj
0 Tc 0 Tw 6.5 0 0 6.5 166.1123 704.3005 Tm
(22)Tj
10 0 0 10 172.6123 701.0005 Tm
(.)Tj
0.0063 Tw -10.6612 -1.2 Td
[(In our study)64.9 (, SAA)-201.5 (values did not depend on SAA1 geno-)]TJ
-0.00011 Tc 0.2198 Tw -1.2 -1.2 Td
(type. Since they were receiving colchicine, our patients\325)Tj
0.0143 Tc 0.3606 Tw 0 -1.2 TD
[(SAA)-570.1 (levels were af)17.8 (fected by the drug as well. )17.8 (The)]TJ
-0.00011 Tc 0.29021 Tw T*
[(SAA/CRP)-503.4 (values were even lower in patients with the)]TJ
0 Tw T*
(SAA1)Tj
/T1_2 1 Tf
0 Tc [-0.2 (\002)]TJ
/T1_1 1 Tf
[0.1 (/)]TJ
/T1_2 1 Tf
[0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.1611 Tw 4.4505 0 Td
(genotype, compared to other SAA1 genotypes.)Tj
-0.0006 Tw -4.4504 -1.2 Td
[(Observations by )36.8 (Y)99.8 (amada, )]TJ
/T1_3 1 Tf
10.4686 0 Td
(et al)Tj
/T1_1 1 Tf
0 Tc 0 Tw 6.5 0 0 6.5 176.1744 632.3005 Tm
(22)Tj
-0.00011 Tc -0.0006 Tw 10 0 0 10 185.168 629.0005 Tm
(and our results suggest that)Tj
0.3136 Tw -13.1168 -1.2 Td
(the increased risk for renal amyloidosis is not directly)Tj
0.2014 Tw T*
[(related to SAA)-396.6 (level. )17.7 (The question of why the SAA1)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 22.8999 0 Td
(\003)Tj
/T1_1 1 Tf
[-0.1 (/)]TJ
/T1_2 1 Tf
[0.2 (\003)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.1241 Tw -22.9 -1.2 Td
(genotype is associated with renal amyloidosis in Japanese)Tj
0.07899 Tw T*
[(patients with RA)-274.2 (and the SAA1)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 13.0322 0 Td
(\002)Tj
/T1_1 1 Tf
[0.2 (/)]TJ
/T1_2 1 Tf
[0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.07899 Tw 1.8685 0 Td
(genotype is associated)Tj
0.327 Tw -14.9008 -1.2 Td
(with renal amyloidosis in FMF patients remains to be)Tj
0 Tw T*
(answered.)Tj
-0.02921 Tw 1.2 -1.2 Td
(Our study confirms an association between the SAA1)Tj
/T1_2 1 Tf
0 Tc 0 Tw 21.2605 0 Td
(\002)Tj
/T1_1 1 Tf
[0.1 (/)]TJ
/T1_2 1 Tf
[0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.3533 Tw -22.4604 -1.2 Td
[(genotype and renal amyloidosis in patients with FMF)79.7 (.)]TJ
-0.0042 Tw T*
[(SAA/CRP)-209.1 (value is a better measure for evaluating the influ-)]TJ
0.0919 Tw T*
(ence of SAA1)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.4 (\002)]TJ
/T1_1 1 Tf
[0.1 (/)]TJ
/T1_2 1 Tf
[0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.0919 Tw 7.7294 0 Td
[(genotype on SAA)-287.1 (level in patients with)]TJ
0.3284 Tw -7.7293 -1.2 Td
[(FMF)79.7 (. )17.7 (Whether greater macrophage uptake or increased)]TJ
0.11909 Tw T*
(\(RA\) fibrilogenesis of the )Tj
/T1_2 1 Tf
0 Tc 0 Tw (\002)Tj
/T1_1 1 Tf
[0.1 (/)]TJ
/T1_2 1 Tf
[0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.11909 Tw 12.9361 0 Td
(isoform plays a role in the)Tj
0.02499 Tw -12.9362 -1.2 Td
[(pathogenesis of amyloidosis in FMF merits further study)64.8 (.)]TJ
/T1_4 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 439.0005 Tm
[(1.)-875.1 (Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever:)]TJ
1.675 -1.25 Td
[(A)-220.1 (survey of 470 cases and review of the literature. )54.8 (Am J Med)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1967;43:227-53.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (The French Consortium. )54.8 (A)-220.1 (candidate gene for FMF)79.7 (. Nature Genet)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1997;17:25-31.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (The International FMF Consortium. )54.8 (Ancient missense mutations in)]TJ
1.675 -1.25 Td
[(a new member of the RoRet gene family are likely to cause FMF)79.7 (.)]TJ
T*
(Cell 1997;90:797-807.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Saatci U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in)]TJ
1.675 -1.25 Td
[(children: report of a lar)17.7 (ge series and discussion of the risk and)]TJ
T*
(prognostic factors of amyloidosis. Eur J Pediatr 1997;156:619-23.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Schwabe )54.8 (AD, Peters RS. Familial Mediterranean fever in)]TJ
1.675 -1.25 Td
[(Armenians: )54.8 (Analysis of 100 cases. Medicine 1974;53:453-62.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Barakat MH, Karnik )54.8 (AM, Majeed HW)91.7 (, El-Sobki NI, Fenech FF)79.7 (.)]TJ
1.675 -1.25 Td
(Familial Mediterranean fever \(recurrent hereditary polyserositis\) in)Tj
T*
[(Arabs. )54.8 (A)-220.1 (study of 175 patients and review of the literature. )]TJ
0 Tc T*
(Q J Med 1986;60:837-47.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Dewalle M, Domingo C, Rozenbaum M, et al. Phenotype-genotype)]TJ
1.675 -1.25 Td
[(correlation in Jewish patients suf)17.7 (fering from familial Mediterranean)]TJ
T*
[(fever)54.8 (. Eur J Hum Genet 1998;6:95-7.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Booth DR, Gillmore JD, Booth SE, Pepys MB, Hawkins PN.)]TJ
1.675 -1.25 Td
[(Pyrin/marenostrin mutations in familial Mediterranean fever)54.8 (. )]TJ
0 Tc T*
(Q J Med 1998;91:603-6.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Y)99.8 (alcinkaya F)79.7 (,)-0.1 ( )54.8 (Akar N, Misirlioglu M. Familial Mediterranean fever:)]TJ
1.675 -1.25 Td
[(amyloidosis and the )17.7 (V)110.8 (al726Ala mutation. N Engl J Med)]TJ
0 Tc 0 Tw T*
(1998;338:993-4.)Tj
-0.00011 Tc 0.02499 Tw 30.825 65.6911 Td
[(10.)-875.1 (Y)99.8 (alcinkaya F)79.7 (, Cakar N, Misirlioglu M, et al. Genotype-phenotype)]TJ
2.175 -1.25 Td
[(correlation in a lar)17.7 (ge group of )17.7 (T)35 (urkish patients with familial)]TJ
T*
(Mediterranean fever: evidence for mutation independent )Tj
T*
(amyloidosis. Rheumatology 2000;39:67-72.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Uhlar CM, )17.7 (Whitehead )54.8 (AS. Serum amyloid )54.8 (A, the major vertebrate)]TJ
2.1381 -1.25 Td
(acute-phase reactant. Eur J Biochem 1999;265:501-23.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Benson MB, Cohen )54.8 (AS. Serum amyloid )54.8 (A)-220.1 (protein in amyloidosis,)]TJ
2.175 -1.25 Td
[(rheumatic and neoplastic diseases. )54.8 (Arthritis Rheum 1979;22:36-42.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Berendes E, M\232llhof)17.7 (f )17.7 (T)74 (,)-0.1 ( van )54.8 (Aken H, Erren M, Deng MC, Loick)]TJ
2.175 -1.25 Td
[(HM. Increased plasma concentration of serum amyloid )54.8 (A: an )]TJ
T*
(indicator of acute phase response after cardiopulmonary bypass.)Tj
T*
(Crit Care Med 1997;25:1527-33.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Sipe JD. Nomenclature Committee of the International Society of)]TJ
2.175 -1.25 Td
[(Amyloidosis. Part 2. Revised nomenclature for serum amyloid )54.8 (A)]TJ
-0.0298 Tw T*
[(\(SAA\). Amyloid )-54.8 (1999;6:67-70.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Liepnieks JJ, Kluve-Beckerman B, Benson MD. Characterization of)]TJ
2.175 -1.25 Td
[(amyloid )54.8 (A)-220.1 (protein in human secondary amyloidosis: the )]TJ
T*
[(predominant deposition of serum amyloid )54.8 (A1. Biochim Biophys)]TJ
T*
(Acta 1995;1270:81-6.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Baba S, Masago SA, )17.7 (T)69.9 (akahashi )17.7 (T)74 (, et al. )54.8 (A)-220.1 (novel allelic variant of)]TJ
2.175 -1.25 Td
[(serum amyloid )54.8 (A. SAA1g: genomic evidence, evolution, frequency)64.8 (,)]TJ
T*
(and implication as a risk factor for reactive systemic amyloidosis.)Tj
T*
(Hum Mol Genet 1995;4:1083-7.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1)]TJ
2.175 -1.25 Td
[(alleles as risk factors in reactive systemic amyloidosis. )54.8 (Amyloid)]TJ
0 Tc 0 Tw T*
(1998;5:262-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Okuda )36.8 (Y)128.9 (,)-0.1 ( )36.8 (Y)99.8 (amada )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (akasugi K, et al. Serum amyloid )54.8 (A)-220.1 (\(SAA\)1,)]TJ
2.175 -1.25 Td
(SAA2 and apolipoprotein E isotype frequencies in rheumatoid)Tj
T*
[(arthritis patients with )54.8 (AA)-220.2 (amyloidosis. R)39.7 (yumachi 1999;39:3-10.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Cazeneuve C, )54.8 (Ajrapetyan H, Papin S, et al. Identification of )]TJ
2.175 -1.25 Td
[(MEFV)91.7 (-independent modifying genetic factors for familial)]TJ
T*
[(Mediterranean fever)54.8 (. )54.8 (Am J Hum Genet 2000;67:1)36.8 (136-43.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (T)35 (unca M, Kirkali G, Soyt\237rk M, )54.8 (Akar S, Pepys MB, Hawkins PN.)]TJ
2.175 -1.25 Td
(Acute phase response and evolution of familial Mediterranean fever)Tj
T*
([letter]. Lancet 1999;353:1415.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Duzova )54.8 (A, Bakkaloglu )54.8 (A, Besbas N, et al. Role of )54.8 (A-SAA)-220.2 (in )]TJ
2.175 -1.25 Td
(monitoring subclinical inflammation and in colchicine dosage in)Tj
T*
[(familial Mediterranean fever)54.8 (. Clin Exp Rheumatol 2003;21:509-14.)]TJ
-2.175 -1.25 Td
[(22.)-875.1 (Y)99.8 (amada )17.7 (T)74 (,)-0.1 ( Okuda )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (akasugi K, Itoh K, Igari J. Relative serum)]TJ
2.175 -1.25 Td
[(amyloid )54.8 (A)-220.1 (\(SAA\) values: the influence of SAA1 genotypes and)]TJ
T*
(corticosteroid treatment in Japanese patients with rheumatoid)Tj
0 Tc T*
[(arthritis. )54.9 (Ann Rheum Dis 2001;60:124-7.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875.1 (Moriguchi M, )17.7 (T)69.9 (erai C, Koseki )36.8 (Y)128.9 (, et al. Influence of genotypes at)]TJ
2.175 -1.25 Td
(SAA1 and SAA2 loci on the development and the length of the)Tj
T*
[(latent period of secondary )54.8 (AA-amyloidosis in patients with )]TJ
T*
(rheumatoid arthritis. Hum Genet 1999;105:360-6.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (Meek RL, Hof)17.7 (fman JS, Benditt EP)110.7 (. )54.8 (Amyloidogenesis: one serum)]TJ
2.175 -1.25 Td
[(amyloid )54.8 (A)-220.1 (isotype is selectively removed from the circulation. )]TJ
0 Tc T*
(J Exp Med 1986;163:499-510.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(25.)-875.1 (Kluve-Beckerman B, )36.8 (Y)99.8 (amada )17.7 (T)74 (, Hardwick J, Liepnieks JJ, Benson)]TJ
2.175 -1.25 Td
[(MD. Dif)17.7 (ferential plasma clearance of murine acute phase serum)]TJ
T*
[(amyloid )54.8 (A)-220.1 (proteins SAA1 and SAA2. Biochem J 1997;322:663-9.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:6)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1142)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_5 8 Tf
120.98 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_6 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
19 0 obj
<>stream
8;Z\7Mf-Ed#iu#8OPcHa)t"\u*ReiQUnF_Z>JfEN_c;-HQ%((mMLF:qo]HVL2smV0
D_#%[_s]N_=+:rO=#2.Ibu&Ig;7[I.W4Gad1pjM_\L[jV^oUi1`8qg\8*r3?4a--F
^rXk9Wb+TRVUk%2ekYTn'P`YD=3%p:QXVs9nd_+dHL+B9*cKITkU[k%d/rPCT`&q9
J_e.A"i@S#_S3p*X[1``Aug,VT:FcIp1PoI>At#bF/a\1Iu.$`I@N=a05G&-]q_ZI
UB(#?4/WRYTC7enW^gu'jG0V*H^u$jRGu\c1[)7$p/XghLiL3BF4ABu-861@nmRPj
#$Zfdo_5rp%eSrd`i=,Ag#@)l34K"pJZMr)epQ;*#fEN)EH"IdiU&=UAeB6](E,!9
#KS<1u\H0p5.V6a*DBOW;1^M4m5!,/>XhM\ol)-G7)h88[jBj3$LW!%WZ
EB?)QWP4H]-7C6t4VZ?n:HpAsDX6M^NkUt\kcK+3)mP&M!,<0\)Xo2_/M"O@C[\oI
O1Dk1(WuM$$B^amN.o4d;K24>U;$&o=c8J/)b,N[+Ck0]:K5tQ*Ce(iTugkDkB4-:
&Ij[j#T0[AZ8NaMI);7NK)dPfn;1P817.SH=[^Q_C=T8m6Qrp#&6q"RJZ.omGK]&i
gf0t'C3[oTKV"+?;4KtH]Oh;nE:8
endstream
endobj
23 0 obj
[/Indexed/DeviceRGB 255 22 0 R]
endobj
22 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
92 0 obj
<>
endobj
47 0 obj
<>
endobj
64 0 obj
<>
endobj
42 0 obj
<>
endobj
10 0 obj
<>
endobj
83 0 obj
<>
endobj
106 0 obj
<>
endobj
11 0 obj
<>
endobj
12 0 obj
<>stream
HLPw9v_lEY=I1s_U B(1'܅wX&zܝp bD@kTjIcN:11yv}oJpv癝w}>|$"#$cLr֚mZ\N{z( i)͏84;R2D+aw|TW7]t>
FS1EQg%ƤUβ*Vq9|a$%9&=)jM1Eέ~}RN)-Ey>ns.>cśr\d)5%ʛlgyUO7;^t
M̂ Ryb#x
TCRFDD0\>bK75&MF"ʠZ!'șnS' g4i5]s""[pSCI*薒2=kk9>Ga?A`3)%y![VRo_qpl{=@XvaG-neٶ^XV 18j`?5Y8)pBcA"2> 0F}L3t7f a;OtG֎mFkݶ3F}||zU
!hq3l
@vc܂%:E2ExP\g5:6ܸmQ}Tsm
Lϵ+KO E@}+8?$P2C jĴf0pGkW3Qiu~uP vLAHOAx!Q#XɃ΅8ЀBąh|p@=V@sWT%V|+ֆx;ʶUwY'ʴH$Zmh(
S:Z/OL1?B"S&ǀ[1U>/ҿ\4l4x<)Kvn)H~엎.k_EVFzofNYm[kl؉^!ƪd "oQ]4T0\Og99ٛH dED݀jlnNo<\"sX|1T
%w(˹;g7'!~L4W
Ʊ˼x'Nũ^ybOj
}8'Yy`!X`>S8YZIHen0[iqX<
_o194O
X29|]/z l8i2;"5lBP'(0Za{bNvTԫǙo$Ai)V;6-3\;]P )OJ+!q4:
\M64Kq@^2__kI#_aƩ}]xpL#u鍮MV@j?ˢ P{PljCT%e\I,ye}lfe&=-N#@o#LtpWn?͟YDF8簜|oo{i-QQ/`fȪgE SZ:[ު k
endstream
endobj
43 0 obj
<>
endobj
76 0 obj
<>stream
HT{PSw7QPjZ"V-Ea<"